Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART NOUVEAU trial of nivolumab + ipilimumab with or without radiotherapy in metastatic esophageal cancer
jRCT1031240461Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in esophageal cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1031240461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240461.